Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer said that Tasocitinib has met primary endpoint in Phase 2 efficacy and safety study, a statistically greater proportion of patients achieving at least a 75% reduction from baseline in PASI (Psoriasis Area and Severity Index) at week 12 in individuals with chronic moderate to severe plaque psoriasis.
Subscribe to our email newsletter
Tasocitinib is a Janus Kinase (JAK) inhibitor. It is believed that the JAK pathways play an important role in the psoriasis disease cascade.
In the trial, at week 12, PASI 75 responses for Tasocitinib 2, 5 and 15 mg twice daily groups were 25%, 40.8% and 66.7% respectively, versus placebo, 2% (all doses, p<0.001).
As early as week 4, treatment with 5 and 15mg twice daily of Tasocitinib improved patient reported health-related quality of life outcomes.
The double-blind, placebo-controlled, dose-ranging Phase 2 study was conducted in 197 adult patients with moderate to severe plaque psoriasis.